Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 340

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma

Open access
Timmers, Henri J.L.M., Kozupa, Anna, Chen, Clara C., Carrasquillo, Jorge A., Ling, Alexander, Eisenhofer, Graeme, Adams, Karen T., Solis, Daniel, Lenders, Jacques W.M., Pacak, Karel·2007·Journal of Clinical Oncology

Abstract

Purpose: Germline mutations of the gene encoding subunit B of the mitochondrial enzyme succinate dehydrogenase (SDHB) predispose to malignant paraganglioma (PGL). Timely and accurate localization of these aggressive tumors is critical for guiding optimal treatment. Our aim is to evaluate the performance of functional imaging modalities in the detection of metastatic lesions of SDHB-associated PGL. Patients and Methods: Sensitivities for the detection of metastases were compared between [18 F]fluorodopamine ([18 F]FDA) and [18 F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET), iodine-123- (123 I) and iodine-131 (131 I) -metaiodobenzylguanidine (MIBG), 111 In-pentetreotide, and Tc-99m-methylene diphosphonate bone scintigraphy in 30 patients with SDHB-associated PGL. Computed tomography (CT) and magnetic resonance imaging (MRI) served as standards of reference. Results: Twenty-nine of 30 patients had metastatic lesions. In two patients, obvious metastatic lesions on functional imaging were missed by CT and MRI. Sensitivity according to patient/body region was 80%/65% for 123 I-MIBG and 88%/70% for [18 F]FDA-PET. False-negative results on 123 I-MIBG scintigraphy and/or [18 F]FDA-PET were not predicted by genotype or biochemical phenotype. [18 F]FDG-PET yielded a by patient/by body region sensitivity of 100%/97%. At least 90% of regions that were false negative on 123 I-MIBG scintigraphy or [18 F]FDA-PET were detected by [18 F]FDG-PET. In two patients, 111 In-pentetreotide scintigraphy detected liver lesions that were negative on other functional imaging modalities. Sensitivities were similar before and after chemotherapy or 131 I-MIBG treatment, except for a trend toward lower post- (60%/41%) versus pretreatment (80%/65%) sensitivity of 123 I-MIBG scintigraphy. Conclusion: With a sensitivity approaching 100%, [18 F]FDG-PET is the preferred functional imaging modality for staging and treatment monitoring of SDHB-related metastatic PGL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.09.6297

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 340

Metadata

Authors
Timmers, H. J. L. M., Kozupa, A., Chen, C. C., Carrasquillo, J. A., Ling, A., Eisenhofer, G., Adams, K. T., Solis, D., Lenders, J. W. M., & Pacak, K.
Venue
Journal of Clinical Oncology
Published
2007-06-01
Volume
25
Issue
16
Pages
2262-2269
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2142974837
Cited by
340
References
31
FWCI
24.16
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma. https://app.cochat.ai/papers/10.1200/jco.2006.09.6297
The paper
Timmers, H. J. L. M., Kozupa, A., Chen, C. C., Carrasquillo, J. A., Ling, A., Eisenhofer, G., Adams, K. T., Solis, D., Lenders, J. W. M., & Pacak, K. (2007). Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.09.6297

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.